Latest Insider Transactions at Mineralys Therapeutics, Inc. (MLYS)
This section provides a real-time view of insider transactions for Mineralys Therapeutics, Inc. (MLYS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Mineralys Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Mineralys Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2025
|
Jon Congleton Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,082
+3.54%
|
$0
$0.54 P/Share
|
|
Nov 20
2025
|
Brian Taylor Slingsby Director |
SELL
Open market or private sale
|
Indirect |
1,000,000
-11.23%
|
$43,000,000
$43.35 P/Share
|
|
Nov 13
2025
|
Alexander M Gold Director |
SELL
Open market or private sale
|
Direct |
12,742
-100.0%
|
$586,132
$46.5 P/Share
|
|
Nov 13
2025
|
Alexander M Gold Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,742
+46.99%
|
$140,162
$11.45 P/Share
|
|
Nov 13
2025
|
Daphne Karydas Director |
SELL
Open market or private sale
|
Direct |
15,000
-83.72%
|
$690,000
$46.09 P/Share
|
|
Nov 13
2025
|
Daphne Karydas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$150,000
$10.2 P/Share
|
|
Nov 12
2025
|
Alexander M Gold Director |
SELL
Open market or private sale
|
Direct |
6,933
-86.06%
|
$318,918
$46.89 P/Share
|
|
Nov 12
2025
|
Alexander M Gold Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,933
+50.0%
|
$69,330
$10.2 P/Share
|
|
Nov 11
2025
|
Alexander M Gold Director |
SELL
Open market or private sale
|
Direct |
15,000
-83.33%
|
$660,000
$44.76 P/Share
|
|
Nov 11
2025
|
Alexander M Gold Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$150,000
$10.2 P/Share
|
|
Nov 11
2025
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
200,000
-4.36%
|
$8,800,000
$44.23 P/Share
|
|
Nov 11
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
119,524
-16.23%
|
$5,139,532
$43.56 P/Share
|
|
Nov 11
2025
|
Adam Scott Levy CFO and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
105,653
+21.31%
|
$1,373,489
$13.97 P/Share
|
|
Oct 15
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,369
-12.72%
|
$445,867
$43.01 P/Share
|
|
Oct 13
2025
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,100
-0.89%
|
$634,200
$42.83 P/Share
|
|
Oct 13
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
10,758
-4.3%
|
$451,836
$42.08 P/Share
|
|
Sep 15
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,367
-6.24%
|
$409,212
$36.19 P/Share
|
|
Sep 04
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
588,235
+50.0%
|
$14,705,875
$25.5 P/Share
|
|
Sep 04
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,176,470
+17.74%
|
$29,411,750
$25.5 P/Share
|
|
Aug 13
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,365
-10.9%
|
$136,380
$12.93 P/Share
|
|
Aug 12
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+5.74%
|
$6,349
$1.08 P/Share
|
|
Jul 30
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
59,925
-16.33%
|
$838,950
$14.9 P/Share
|
|
Jul 29
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
807
-0.42%
|
$11,298
$14.0 P/Share
|
|
Jul 28
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
12,946
-6.27%
|
$181,244
$14.04 P/Share
|
|
Jul 14
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,366
-10.4%
|
$159,124
$14.59 P/Share
|
|
Jul 14
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+5.49%
|
$6,349
$1.08 P/Share
|
|
Jul 11
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
10,758
-4.95%
|
$150,612
$14.45 P/Share
|
|
Jul 11
2025
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,884
-1.84%
|
$222,376
$14.51 P/Share
|
|
Jun 13
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,366
-10.06%
|
$159,124
$14.6 P/Share
|
|
Jun 12
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,348
+5.32%
|
$6,348
$1.08 P/Share
|
|
May 14
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,366
-9.63%
|
$170,490
$15.29 P/Share
|
|
May 12
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+5.1%
|
$6,349
$1.08 P/Share
|
|
Apr 14
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,366
-4.7%
|
$159,124
$14.26 P/Share
|
|
Apr 14
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,348
+4.91%
|
$6,348
$1.08 P/Share
|
|
Apr 11
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
10,757
-4.76%
|
$129,084
$12.06 P/Share
|
|
Apr 11
2025
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,319
-1.75%
|
$183,828
$12.19 P/Share
|
|
Apr 01
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
55,771
-11.93%
|
$836,565
$15.93 P/Share
|
|
Apr 01
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,606
+0.92%
|
$1,606
$1.08 P/Share
|
|
Mar 13
2025
|
Brian Taylor Slingsby Director |
BUY
Open market or private purchase
|
Indirect |
259,259
+2.83%
|
$3,370,367
$13.5 P/Share
|
|
Mar 13
2025
|
Samsara Bio Capital Gp, LLC |
BUY
Open market or private purchase
|
Indirect |
600,000
+9.56%
|
$7,800,000
$13.5 P/Share
|
|
Mar 13
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
600,000
+9.56%
|
$7,800,000
$13.5 P/Share
|
|
Mar 13
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,296,296
+23.25%
|
$16,851,848
$13.5 P/Share
|
|
Mar 12
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+3.58%
|
$6,349
$1.08 P/Share
|
|
Feb 12
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,348
+3.72%
|
$6,348
$1.08 P/Share
|
|
Jan 13
2025
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,333
-2.05%
|
$164,997
$9.06 P/Share
|
|
Jan 13
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,367
+3.53%
|
$0
$0.81 P/Share
|
|
Jan 13
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
10,757
-2.27%
|
$96,813
$9.36 P/Share
|
|
Dec 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+3.32%
|
$0
$0.54 P/Share
|
|
Nov 11
2024
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,026
-3.44%
|
$75,390
$15.0 P/Share
|
|
Nov 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,043
+3.38%
|
$0
$0.81 P/Share
|